Z. Eltahir

发表

KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer

D. Tait, Gina Brown, C. Braconi, 2018, Scientific Reports.

HER 2 in high-risk rectal cancer patients treated in EXPERT-C , a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin ( CAPOX ) and chemoradiotherapy ( CRT ) with or without cetuximab

J. Tabernero, A. Wotherspoon, D. Cunningham, 2013 .

Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice

M. Gerlinger, C. Braconi, A. Wotherspoon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of secondary bile acids in neoplastic development in the oesophagus.

G. Jenkins, J. Baxter, J. Cronin, 2010, Biochemical Society transactions.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy

A. Wotherspoon, B. Glimelius, I. Chau, 2013 .

Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial

M. Rugge, M. Fassan, M. Nankivell, 2017, JAMA oncology.

Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus.

G. Jenkins, J. Baxter, J. Parry, 2007, Carcinogenesis.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

J. Tabernero, A. Wotherspoon, D. Cunningham, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are important mediators of reflux-induced cell signalling in esophageal cells.

J. Baxter, A. Griffiths, Z. Eltahir, 2012, Carcinogenesis.

The genomic landscape of oesophagogastric junctional adenocarcinoma

A. Ashworth, N. Orr, A. Wotherspoon, 2013, The Journal of pathology.

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Andrea Sottoriva, Nina Tunariu, Paul Workman, 2018, Science.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Nina Tunariu, Andrea Lampis, Mihaela Rata, 2017, Gut.

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

G. G. Van den Eynden, P. Vermeulen, L. Dirix, 2016, Nature Medicine.

Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment

A. Bowcock, A. Wotherspoon, D. Cunningham, 2017, Oncotarget.

Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

J. Reis-Filho, D. Smith, M. Band, 2013, European journal of cancer.

Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer

M. Fassan, M. Greaves, C. Maley, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

D. Tait, J. Tabernero, C. Braconi, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

C. Croce, P. Gasparini, L. Cascione, 2017, Gastroenterology.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

C. Croce, P. Gasparini, L. Cascione, 2017, Gastroenterology.

Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett’s oesophagus

G. Jenkins, J. Baxter, J. Cronin, 2012, Clinical and Translational Oncology.

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

J. Reis-Filho, A. Wotherspoon, D. Cunningham, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.

J. Baxter, J. Cronin, T. Thomas, 2008, Mutagenesis.

Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment

A. Bowcock, A. Wotherspoon, D. Cunningham, 2017, Oncotarget.

Evaluation of Angiogenesis by Using CD105 and CD34 in Sudanese Breast Cancer Patients.

Asaad Mohammed Babker, Z. Eltahir, Hussain G. Ahmed, 2021, Pakistan journal of biological sciences : PJBS.

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

D. Tait, J. Tabernero, C. Braconi, 2016, Carcinogenesis.

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.

J. Reis-Filho, A. Wotherspoon, R. Wong, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: The potential role of anti-oxidants in Barrett's oesophagus.

G. Jenkins, J. Baxter, J. Parry, 2007, Carcinogenesis.